Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GSK | London | GBP | Real-time | |
GSKl | BATS Europe | GBP | Delayed | |
GSK | NYSE | USD | Real-time | |
GLAXF | OTC Markets | USD | Delayed | |
GSKN | Mexico | MXN | Delayed | |
GS70y | Frankfurt | EUR | Delayed | |
GS71 | TradeGate | EUR | Delayed | |
GS71 | Frankfurt | EUR | Delayed | |
GS71 | Xetra | EUR | Delayed | |
GSKm | Buenos Aires | ARS | Delayed | |
G1SK34 | B3 | BRL | Delayed |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Emma N. Walmsley | 51 | 2011 | CEO & Director |
Jonathan Richard Symonds | 62 | 2019 | Non-Executive Chairman |
Anne C. Beal | 61 | 2021 | Independent Non-Executive Director |
Harry C. Dietz | 65 | 2022 | Independent Non-Executive Director |
Elizabeth McKee Anderson | 66 | 2022 | Independent Non-Executive Director |
Jesse L. Goodman | 71 | 2016 | Independent Non-Executive Director |
Julie Brown | 61 | 2023 | CFO & Executive Director |
Hal V. Barron | 60 | 2018 | Non-Executive Director |
Vishal Sikka | 56 | 2022 | Independent Non-Executive Director |
Charles A. Bancroft | 65 | 2020 | Senior Independent Non-Executive Director |
Wendy Becker | 59 | 2023 | Independent Non-Executive Director |
Tsun-Huei Lee | 60 | 2024 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review